Latest Lymphoid leukemia Stories
June 5 - June 25 campaign to help in the fight against blood cancer SAN BERNARDINO, Calif., June 5, 2013 /PRNewswire/ -- The Leukemia & Lymphoma Society is teaming up once again with Stater Bros. Charities for the sixth year of The Leukemia & Lymphoma Society's "Light The Night" fundraising campaign to raise awareness and funds for Leukemia, Hodgkin and Non-Hodgkin Lymphoma, Myeloma and Myelodysplastic Syndromes. (Logo:...
Designation granted in the treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma with a genetic mutation, del17p RARITAN, N.J., April 8, 2013 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen) announced today that the U.S. Food and Drug Administration (FDA) has granted a third Breakthrough Therapy Designation for the investigational oral Bruton's tyrosine kinase (BTK) inhibitor ibrutinib. Ibrutinib has been granted Breakthrough...
An international study coordinated at the IRCM finds a possible alternative treatment to significantly reduce the adverse effects of chemotherapy An international research team coordinated at the IRCM in Montréal found a possible alternative treatment for lymphoid leukemia. Led by Dr. Tarik Möröy, the IRCM’s President and Scientific Director, the team discovered a molecule that represents the disease’s “Achilles’ heel” and could be targeted to develop a new approach that would...
CINCINNATI, Feb. 11, 2013 /PRNewswire-USNewswire/ -- Discovering what they call the "Achilles' heel" for lymphoid leukemia, an international research team has tested a possible alternative treatment that eradicated the disease in mouse models. (Logo: http://photos.prnewswire.com/prnh/20110406/MM79025LOGO) Reporting their results Feb. 11 in the journal Cancer Cell, the scientists said the targeted molecular therapy described in their study could have direct implications for current...
ATLANTA, Dec. 9, 2012 /PRNewswire/ -- By reprogramming a 7-year-old girl's own immune cells to attack an aggressive form of childhood leukemia, a pediatric oncologist has achieved a complete response in his patient, who faced grim prospects when she relapsed after conventional treatment. The innovative experimental therapy used bioengineered T cells, custom-designed to multiply rapidly in the patient, and then destroy leukemia cells. After the treatment, the child's doctors found...
AMSTERDAM, June 15, 2012 /PRNewswire/ -- Dr Alan Ramsay will present findings of a study in patients with Chronic Lymphocytic Leukemia that will contribute to the design of immunotherapeutic strategies leading to the killing of cancer cells at the 17th Congress of the European Hematology Association in Amsterdam. T cell activation is essential for immunity including the recognition and killing of abnormal target cells such as cancerous cells. T cell activity is tightly...
In the news release, Amgen's BiTE® Antibody Blinatumomab (AMG 103) Achieved High Rate of Complete Response in Adult Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, issued 16-May-2012 by Amgen over PR Newswire, we are advised by the company that the third paragraph now includes additional safety information. The complete, corrected release follows: Amgen's BiTE® Antibody Blinatumomab (AMG 103) Achieved High Rate Of Complete Response In Adult Patients With Relapsed Or...
THOUSAND OAKS, Calif., May 16, 2012 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced updated results from a Phase 2 study that showed treatment with blinatumomab (AMG 103) helped achieve a high-rate of complete response (CR) in 72 percent of adult patients with relapsed or refractory B-precursor acute lymphoblastic leukemia (ALL) treated in the study. Blinatumomab is the first of a new class of agents called bi-specific T cell engagers (BiTE®) antibodies, designed to harness...
According to court documents, on Jan. 18th, 2012 Norvel Dorsey, a Texas man, filed the lawsuit No. B-0191669 in Jefferson County District Court, Texas. Mr. Dorsey accuses DuPont De Nemours, Exxon Mobil Corp. and some of its subsidiaries, Foster Wheeler Energy Corp., Gulf Oil Corp., Texaco, U.S. Steel, Chevron U.S.A., and 4520 Corp. alleging that he developed leukemia from benzene exposure. Benzene is a petroleum product, originally manufactured from coal tar that is used as a component in...
DALLAS, December 8, 2011 /PRNewswire/ -- The report "Chronic Lymphocytic Leukemia Therapeutics Market in G8 Countries (2010 - 2020)" analyzes and studies the major market drivers, restraints, and opportunities in geographies such as North America, Europe, and Japan. Browse market data tables and in-depth TOC on "Chronic Lymphocytic Leukemia Therapeutics Market in G8 Countries (2010 - 2020)"....
